1. China In Vitro Diagnostics Market Outlook to 2018- Clinical
Chemistry Genetic Testing, Haematology, Histology and
Cytology, Immuno Chemistry, Infectious Immunology and
Microbiology Culture
Report Details:
Published:November 2012
No. of Pages: 283
Price: Single User License – US$2500
China In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing,
Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and
Microbiology Culture
Summary
GlobalData’s new report, “China In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry
Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious
Immunology and Microbiology Culture” provides key market data on the China In Vitro Diagnostics
market. The report provides value (USD million) data for each segment and sub-segment within
seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And
Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also
provides company shares and distribution shares data for each of the aforementioned market
categories. The report is supplemented with global corporate-level profiles of the key market
participants with information on company financials and pipeline products, wherever available.
This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
- Market size and company share data for In Vitro Diagnostics market categories – Clinical
Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious
Immunology and Microbiology Culture.
- Annualized market revenues (USD million) data for each of the segments and sub-segments
within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.

2. - 2011 company shares and distribution shares data for each of the seven market categories.
- Global corporate-level profiles of key companies operating within the China In Vitro
Diagnosticsmarket.
- Key players covered include Siemens Healthcare, Sysmex Corporation, F. Hoffmann-La Roche
Ltd., Abbott Laboratories, Shanghai Kehua Bio-engineering Co., Ltd., Beckman Coulter, Inc. and
others.
Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for
strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the China In Vitro Diagnostics
competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to
register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product
distribution – Identify, understand and capitalize.
Get your copy of this report @
http://www.reportsnreports.com/reports/210644-china-in-vitro-diagnostics-market-outlook-to-2018-clinical-
chemistry-genetic-testing-haematology-histology-and-cytology-immuno-chemistry-infectious-immunology-and-
microbiology-culture.html
Major points covered in Table of Contents of this report include
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 10
1.2 List of Figures 14
2 Introduction 17
2.1 What is This Report About? 17
3 In Vitro Diagnostics In China 18
3.1 In Vitro Diagnostics, Market Segmentation 18
3.2 In Vitro Diagnostics, China, Overall Revenue ($m), USD Constant, 2004-2018 19
3.3 In Vitro Diagnostics Market, China, Revenue Mix ($m), 2011 20
3.4 In Vitro Diagnostics Market, China, Category Contribution (%), 2011 21
3.5 In Vitro Diagnostics, China, Company Share (2010-2011) 28
4 Clinical Chemistry In China 30
4.1 Clinical Chemistry, Market Segmentation 30
4.2 Clinical Chemistry Market, China, Revenue Mix ($m), 2011 31
4.3 Clinical Chemistry Market, China, Segment Contribution (%), 2011 32
4.4 Clinical Chemistry Overall Revenue, (2004-2018) 33
4.4.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 37
4.4.2 Urine Analysis, Revenue (2004-2018) 41

3. 4.5 Clinical Chemistry Distribution Share (2010-2011) 45
4.6 Clinical Chemistry, China, Company Share (2010-2011) 46
5 Genetic Testing In China 48
5.1 Genetic Testing, Market Segmentation 48
5.2 Genetic Testing Market, China, Revenue Mix ($m), 2011 49
5.3 Genetic Testing Market, China, Segment Contribution (%), 2011 50
5.4 Genetic Testing Overall Revenue, (2004-2018) 51
5.5 Genetic Testing Distribution Share (2010-2011) 55
5.6 Genetic Testing, China, Company Share (2010-2011) 56
6 Haematology In China 58
6.1 Haematology Market, Market Segmentation 58
6.2 Haematology Market, China, Revenue Mix ($m), 2011 59
6.3 Haematology Market, China, Segment Contribution (%), 2011 60
6.4 Haematology Overall Revenue, (2004-2018) 61
6.4.1 Haematology Reagents, Revenue (2004-2018) 65
6.4.2 Immunohaematology, Revenue (2004-2018) 69
6.4.3 Haemostasis, Revenue (2004-2018) 73
6.4.4 Haematology Rapid Tests, Revenue (2004-2018) 77
6.4.5 Haematology Cell Counters, Revenue (2004-2018) 81
6.5 Haematology Distribution Share (2010-2011) 85
6.6 Haematology, China, Company Share (2010-2011) 86
7 Histology And Cytology In China 88
7.1 Histology and Cytology Market, Market Segmentation 88
7.2 Histology And Cytology Market, China, Revenue Mix ($m), 2011 89
7.3 Histology And Cytology Market, China, Segment Contribution (%), 2011 90
7.4 Histology And Cytology Overall Revenue, (2004-2018) 91
7.5 Histology And Cytology Distribution Share (2010-2011) 95
7.6 Histology And Cytology, China, Company Share (2010-2011) 96
8 Immuno Chemistry In China 98
8.1 Immuno Chemistry Market, China, Revenue Mix ($m), 2011 98
8.2 Immuno Chemistry Market, China, Segment Contribution (%), 2011 99
8.3 Immuno Chemistry Overall Revenue, (2004-2018) 100
8.3.1 Disease Specific Immunochemistry, Revenue (2004-2018) 104
8.3.2 Drugs of Abuse / Toxicology, Revenue (2004-2018) 108
8.3.3 Endocrinology Tests, Revenue (2004-2018) 112
8.3.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 116
8.3.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 120
8.3.6 Immunochemistry Analyzers, Revenue (2004-2018) 124
8.4 Immuno Chemistry Distribution Share (2010-2011) 128
8.5 Immuno Chemistry, China, Company Share (2010-2011) 129
9 Infectious Immunology In China 131
9.1 Infectious Immunology, Market Segmentation 131

4. 9.2 Infectious Immunology Market, China, Revenue Mix ($m), 2011 132
9.3 Infectious Immunology Market, China, Segment Contribution (%), 2011 133
9.4 Infectious Immunology Overall Revenue, (2004-2018) 134
9.4.1 Infectious Immunology Rapid Tests, Revenue (2004-2018) 138
9.5 Infectious Immunology Distribution Share (2010-2011) 142
9.6 Infectious Immunology, China, Company Share (2010-2011) 143
10 Microbiology Culture In China 145
10.1 Microbiology Culture, Market Segmentation 145
10.2 Microbiology Culture Market, China, Revenue Mix ($m), 2011 146
10.3 Microbiology Culture Market, China, Segment Contribution (%), 2011 147
10.4 Microbiology Culture Overall Revenue, (2004-2018) 148
10.4.1 Microbiology Analyzers, Revenue (2004-2018) 152
10.5 Microbiology Culture Distribution Share (2010-2011) 156
10.6 Microbiology Culture, China, Company Share (2010-2011) 157
11 Overview of Key Companies in China In Vitro Diagnostics Market 159
11.1 Siemens Healthcare 159
11.1.1 Company Overview 159
11.1.2 Share in the China In Vitro Diagnostics Market 159
11.2 Sysmex Corporation 160
11.2.1 Company Overview 160
11.2.2 Share in the China In Vitro Diagnostics Market 160
11.3 F. Hoffmann-La Roche Ltd. 161
11.3.1 Company Overview 161
11.3.2 Share in the China In Vitro Diagnostics Market 161
11.4 Abbott Laboratories 162
11.4.1 Company Overview 162
11.4.2 Share in the China In Vitro Diagnostics Market 162
11.5 Shanghai Kehua Bio-engineering Co., Ltd. 163
11.5.1 Company Overview 163
11.5.2 Share in the China In Vitro Diagnostics Market 163
11.6 Beckman Coulter, Inc. 164
11.6.1 Company Overview 164
11.6.2 Share in the China In Vitro Diagnostics Market 164
11.7 Mindray Medical International Limited 165
11.7.1 Company Overview 165
11.8 Beckman Coulter, Inc. 165
11.8.1 Company Overview 165
11.9 Ortho-Clinical Diagnostics Inc. 166
11.9.1 Company Overview 166
11.10 Bio-Rad Laboratories, Inc. 166
11.10.1 Company Overview 166
11.11 bioMerieux S.A. 167

5. 11.11.1 Company Overview 167
11.12 Becton, Dickinson and Company 167
11.12.1 Company Overview 167
11.13 Olympus Corporation 168
11.13.1 Company Overview 168
11.14 Da An Gene Co., Ltd. 168
11.14.1 Company Overview 168
11.15 DiaSorin S.p.A 169
11.15.1 Company Overview 169
11.16 Alere Inc. 169
11.16.1 Company Overview 169
11.17 PerkinElmer, Inc. 170
11.17.1 Company Overview 170
11.18 Danaher Corporation 170
11.18.1 Company Overview 170
11.19 Horiba, Ltd. 171
11.19.1 Company Overview 171
11.20 Gen-Probe Incorporated 171
11.20.1 Company Overview 171
11.21 Qiagen N.V. 172
11.21.1 Company Overview 172
11.22 Nihon Kohden Corporation 172
11.22.1 Company Overview 172
11.23 Grifols, S.A. 173
11.23.1 Company Overview 173
11.24 Diagnostica Stago, Inc. 173
11.24.1 Company Overview 173
11.25 Thermo Fisher Scientific Inc. 174
11.25.1 Company Overview 174
11.26 Life Technologies Corporation 174
11.26.1 Company Overview 174
12 In Vitro Diagnostics Market Pipeline Products 175
12.1 Clinical Chemisty Market Pipeline Products 175
12.2 Immuno Chemistry Market Pipeline Products 178
12.3 Haematology Market Pipeline Products 189
12.4 Infectious Immunology Market Pipeline Products 191
12.5 Microbiology Culture Market Pipeline Products 198
12.6 Histology And Cytology Market Pipeline Products 199
12.7 Genetic Testing Market Pipeline Products 200
13 Financial Deals Landscape 205
13.1 Acquisition 205
13.1.1 PerkinElmer Acquires Shanghai Haoyuan Biotech From Medigen Biotech For $38 Million

6. 205
13.1.2 SK Telecom To Acquire 49% Stake In Xi''an Tianlong, In-vitro Diagnostics Company 207
13.1.3 Fresenius Acquires 70% Stake In Huangshi Lishizhen Medicine Group Wuhan Xisu
Pharma From Huangshi Lishizhen Medicine Group Wuhan Lishizhen Medicine 208
13.1.4 Wuhan Humanwell Hi-tech Industry To Acquire 80% Stake In Beijing Baron Medical
Equipment For $123 Million 209
13.1.5 OriGene Technologies Acquires Beijing Zhongshan Golden Bridge Biotechnology,
Pathology Testing Products Provider 210
13.1.6 Mindray Medical Completes Acquisition Of Controlling Stake In Hunan Changsha Tiandiren
Biotech For $3 Million 211
13.2 Partnerships 212
13.2.1 bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 212
13.2.2 Abaxis Enters Into Distribution Agreement With Abbott Point of Care For Piccolo Blood
Chemistry System 214
13.2.3 Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For
Archimedes Particle Metrology System 215
13.2.4 Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 216
13.2.5 BG Medicine Enters Into Agreement With Wuhan Kindstar Diagnostics For Galectin-3
Testing 217
13.2.6 BioDot Enters Into Co-Marketing Agreement With JOT Automation 218
13.2.7 BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology
Assays 219
13.2.8 Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress
Dx Test 220
13.2.9 Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology
222
13.2.10 CML HealthCare Enters Into Agreement With MaRS Innovation 223
13.2.11 Akrivis Technologies Enters Into Co-Development Agreement With United States
Biological 224
13.2.12 Qiagen Enters Into Co-Marketing Agreement With Lepu Medical 225
13.2.13 Castle Biosciences Enters Into Licensing Agreement With Brigham and Women''s Hospital
For Mesothelioma Test 226
13.2.14 Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein
Array Products 227
13.2.15 GeneCentric Diagnostics Enters Into Licensing Agreement With University of North
Carolina 228
13.2.16 Edan Instruments And Edan Diagnostics Form Joint Venture With Xizeng Shi 229
13.2.17 Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB
Test 230
13.2.18 Ahn-Gook Pharma Enters Into Licensing Agreement With Ceragem Medisys 231
13.2.19 SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For
PhenoFluor 232

7. 13.2.20 Sysmex Asia Pacific Enters Into Distribution Agreement With DiaSys Diagnostic Systems
233
13.2.21 Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 234
13.2.22 MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 235
13.2.23 NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus
236
13.2.24 Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 238
13.2.25 Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POC
Test 239
13.2.26 One Lambda Enters Into Co-Marketing Agreement With CellTrend 240
13.2.27 Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For
ALK Cancer Biomarker 241
13.2.28 Insight Genetics Enters Into Licensing Agreement With Kindstar Globalgene Technology
For ALK Screen Biomaker 242
13.2.29 Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 243
13.2.30 Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker
244
13.2.31 Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor Cell
Technology 245
13.2.32 Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 246
13.2.33 Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange
PCR Kit 247
13.2.34 Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 248
13.2.35 Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For
Pressure Cycling Technology 249
13.2.36 LipoScience Enters Into Licensing Agreement With Cleveland Clinic 250
13.2.37 GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact
Cyclotron And PET Tracer System 251
13.2.38 GE Healthcare Enters Into Research Agreement With Clino 252
13.2.39 NexDx Enters Into Licensing Agreement With University of California For Epigenetic
Biomarkers 253
13.2.40 Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 254
13.2.41 GeneNews Forms Joint Venture With Shanghai Biochip For Sentinel Centre For
Personalized Medicine 255
13.2.42 Life Technologies Enters Into Joint Venture Agreement With DaAn Gene 257
14 Recent Developments 258
14.1 Strategy And Business Planning 258
14.1.1 Nov 14, 2012: Promega Opens New Shanghai Facility 258
14.1.2 Sep 24, 2012: Novo Nordisk Invests $100m To Expand R&D Facilities In Beijing, China 258
14.1.3 Jun 21, 2012: Gentris Partners With Shanghai Institutes of Preventative Medicine 259
14.2 Research And Development 260
14.2.1 Aug 02, 2012: Covidien Opens $45m R&D Facility In China 260

8. 14.2.2 Jul 11, 2012: Refine Technology And Wuhan Institute Of Biological Products Collaborate
To Improve Yield Of Vaccine Manufacturing 261
14.3 Government and Public Interest 261
14.3.1 Aug 03, 2012: China Launches Five-Year Cancer Screening Program 261
14.3.2 Jan 19, 2012: Mindray Medical To Exhibit At Arab Health 2012 In Dubai 262
14.3.3 Dec 28, 2011: Mindray Medical To Present At Upcoming Investor Conferences 262
14.4 Product News 262
14.4.1 Nov 12, 2012: Corgenix Receives Regulatory Approval For Sale Of AspirinWorks In China
262
14.4.2 May 18, 2012: Grifols Signs Cooperation Agreement With Shanghai Blood Bank To Use
BLOODchip Genetic Test In Transfusional Compatibility Studies 263
14.4.3 May 15, 2012: BGI Installs Roche GS FLX+ System To Enhance Long Read Sequencing
Capabilities For Genome And Transcriptome Research 264
14.4.4 Apr 05, 2012: EKF Announces Issuance Of Chinese Patent For Hemo Control
Microcuvettes 264
14.4.5 Mar 19, 2012: BioPorto Receives Chinese SFDA Approval For NGAL Test Through Its
Distribution Partner 265
14.4.6 Mar 08, 2012: QIAGEN Expands Access To digene HPV Test In China Through Co-
Marketing Agreement With KingMed Diagnostics 265
14.4.7 Feb 17, 2012: KHB Launches Enterovirus, EV71, CA16 RNA PCR Detection Kit 266
14.4.8 Feb 17, 2012: KHB Receives New CE Mark For Automatic Clinical Chemistry Analyzer 266
14.4.9 Feb 15, 2012: Affymetrix Receives China’s SFDA Approval For Its GeneChip System
3000Dx v.2 266
15 Appendix 267
15.1 Definitions of Markets Covered in the Report 268
15.1.1 In Vitro Diagnostics 268
15.2 Research Methodology 280
15.3 Secondary Research 280
15.4 Primary Research 281
15.5 Models 281
15.6 Forecasts 282
15.7 Expert Panels 282
15.8 GlobalData Consulting 282
15.9 Currency Conversion 283
15.10 Contact Us 283
15.11 Disclaimer 283
1.1 List of Tables
Table 1: In Vitro Diagnostics, China, Overall Revenue ($m), USD Constant, 2004-2018 19
Table 2: In Vitro Diagnostics Market, China, Category Contribution (%), 2011 21
Table 3: In Vitro Diagnostics Market, China, Cross-Category Analysis, 2004-2018 23
Table 4: In Vitro Diagnostics, China, Overall Revenue ($m), USD Constant, Historic, 2004-2011 25

9. Table 5: In Vitro Diagnostics, China, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
27
Table 6: In Vitro Diagnostics, China, Company Share by Revenue ($m), USD Constant, 2010-
2011 29
Table 7: Clinical Chemistry Market, China, Segment Contribution (%), 2011 32
Table 8: Clinical Chemistry, China, Revenue ($m) USD Constant, by Segment, Historic, 2004-
2011 34
Table 9: Clinical Chemistry, China, Revenue ($m) USD Constant, by Segment, Forecast, 2011-
2018 36
Table 10: Clinical Chemisty Analyzers, China, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 38
Table 11: Clinical Chemisty Analyzers, China, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 40
Table 12: Urine Analysis, China, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-
2011 42
Table 13: Urine Analysis, China, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-
2018 44
Table 14: Clinical Chemistry, China, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 45
Table 15: Clinical Chemistry, China, Company Share by Revenue ($m), USD Constant, 2010-
2011 47
Table 16: Genetic Testing Market, China, Segment Contribution (%), 2011 50
Table 17: Genetic Testing, China, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
52
Table 18: Genetic Testing, China, Revenue ($m) USD Constant, by Segment, Forecast, 2011-
2018 54
Table 19: Genetic Testing, China, Distribution Share by Revenue ($m), USD Constant, 2010-2011
55
Table 20: Genetic Testing, China, Company Share by Revenue ($m), USD Constant, 2010-2011
57
Table 21: Haematology Market, China, Segment Contribution (%), 2011 60
Table 22: Haematology, China, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 62
Table 23: Haematology, China, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
64
Table 24: Haematology Reagents, China, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 66
Table 25: Haematology Reagents, China, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 68
Table 26: Immunohaematology, China, Revenue ($m) USD Constant, by Sub-Segment, Historic,
2004-2011 70
Table 27: Immunohaematology, China, Revenue ($m) USD Constant, by Sub-Segment, Forecast,
2011-2018 72

10. Table 28: Haemostasis, China, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-
2011 74
Table 29: Haemostasis, China, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-
2018 76
Table 30: Haematology Rapid Tests, China, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 78
Table 31: Haematology Rapid Tests, China, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 80
Table 32: Haematology Cell Counters, China, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 82
Table 33: Haematology Cell Counters, China, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 84
Table 34: Haematology, China, Distribution Share by Revenue ($m), USD Constant, 2010-2011
85
Table 35: Haematology, China, Company Share by Revenue ($m), USD Constant, 2010-2011 87
Table 36: Histology And Cytology Market, China, Segment Contribution (%), 2011 90
Table 37: Histology And Cytology, China, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 92
Table 38: Histology And Cytology, China, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 94
Table 39: Histology And Cytology, China, Distribution Share by Revenue ($m), USD Constant,
2010-2011 95
Table 40: Histology And Cytology, China, Company Share by Revenue ($m), USD Constant,
2010-2011 97
Table 41: Immuno Chemistry Market, China, Segment Contribution (%), 2011 99
Table 42: Immuno Chemistry, China, Revenue ($m) USD Constant, by Segment, Historic, 2004-
2011 101
Table 43: Immuno Chemistry, China, Revenue ($m) USD Constant, by Segment, Forecast, 2011-
2018 103
Table 44: Disease Specific Immunochemistry, China, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 105
Table 45: Disease Specific Immunochemistry, China, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 107
Table 46: Drugs of Abuse / Toxicology, China, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 109
Table 47: Drugs of Abuse / Toxicology, China, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 111
Table 48: Endocrinology Tests, China, Revenue ($m) USD Constant, by Sub-Segment, Historic,
2004-2011 113
Table 49: Endocrinology Tests, China, Revenue ($m) USD Constant, by Sub-Segment, Forecast,
2011-2018 115
Table 50: Immunochemistry Rapid Tests, China, Revenue ($m) USD Constant, by Sub-Segment,

11. Historic, 2004-2011 117
Table 51: Immunochemistry Rapid Tests, China, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 119
Table 52: Therapeutic Drug Monitoring, China, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 121
Table 53: Therapeutic Drug Monitoring, China, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 123
Table 54: Immunochemistry Analyzers, China, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 125
Table 55: Immunochemistry Analyzers, China, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 127
Table 56: Immuno Chemistry, China, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 128
Table 57: Immuno Chemistry, China, Company Share by Revenue ($m), USD Constant, 2010-
2011 130
Table 58: Infectious Immunology Market, China, Segment Contribution (%), 2011 133
Table 59: Infectious Immunology, China, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 135
Table 60: Infectious Immunology, China, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 137
Table 61: Infectious Immunology Rapid Tests, China, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 139
Table 62: Infectious Immunology Rapid Tests, China, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 141
Table 63: Infectious Immunology, China, Distribution Share by Revenue ($m), USD Constant,
2010-2011 142
Table 64: Infectious Immunology, China, Company Share by Revenue ($m), USD Constant, 2010-
2011 144
Table 65: Microbiology Culture Market, China, Segment Contribution (%), 2011 147
Table 66: Microbiology Culture, China, Revenue ($m) USD Constant, by Segment, Historic, 2004-
2011 149
Table 67: Microbiology Culture, China, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 151
Table 68: Microbiology Analyzers, China, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 153
Table 69: Microbiology Analyzers, China, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 155
Table 70: Microbiology Culture, China, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 156
Table 71: Microbiology Culture, China, Company Share by Revenue ($m), USD Constant, 2010-
2011 158
Table 72: Clinical Chemisty Market Pipeline Products 175

12. Table 73: Immuno Chemistry Market Pipeline Products 178
Table 74: Haematology Market Pipeline Products 189
Table 75: Infectious Immunology Market Pipeline Products 191
Table 76: Microbiology Culture Market Pipeline Products 198
Table 77: Histology And Cytology Market Pipeline Products 199
Table 78: Genetic Testing Market Pipeline Products 200
Table 79: PerkinElmer Acquires Shanghai Haoyuan Biotech From Medigen Biotech For $38
Million 205
Table 80: SK Telecom To Acquire 49% Stake In Xi''an Tianlong, In-vitro Diagnostics Company 207
Table 81: Fresenius Acquires 70% Stake In Huangshi Lishizhen Medicine Group Wuhan Xisu
Pharma From Huangshi Lishizhen Medicine Group Wuhan Lishizhen Medicine 208
Table 82: Wuhan Humanwell Hi-tech Industry To Acquire 80% Stake In Beijing Baron Medical
Equipment For $123 Million 209
Table 83: OriGene Technologies Acquires Beijing Zhongshan Golden Bridge Biotechnology,
Pathology Testing Products Provider 210
Table 84: Mindray Medical Completes Acquisition Of Controlling Stake In Hunan Changsha
Tiandiren Biotech For $3 Million 211
Table 85: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 212
Table 86: Abaxis Enters Into Distribution Agreement With Abbott Point of Care For Piccolo Blood
Chemistry System 214
Table 87: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For
Archimedes Particle Metrology System 215
Table 88: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 216
Table 89: BG Medicine Enters Into Agreement With Wuhan Kindstar Diagnostics For Galectin-3
Testing 217
Table 90: BioDot Enters Into Co-Marketing Agreement With JOT Automation 218
Table 91: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology
Assays 219
Table 92: Med BioGene Amends Licensing Agreement With Precision Therapeutics For
LungExpress Dx Test 220
Table 93: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon
Biotechnology 222
Table 94: CML HealthCare Enters Into Agreement With MaRS Innovation 223
Table 95: Akrivis Technologies Enters Into Co-Development Agreement With United States
Biological 224
Table 96: Qiagen Enters Into Co-Marketing Agreement With Lepu Medical 225
Table 97: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women''s
Hospital For Mesothelioma Test 226
Table 98: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein
Array Products 227
Table 99: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North
Carolina 228

13. Table 100: Edan Instruments And Edan Diagnostics Form Joint Venture With Xizeng Shi 229
Table 101: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium
TB Test 230
Table 102: Ahn-Gook Pharma Enters Into Licensing Agreement With Ceragem Medisys 231
Table 103: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For
PhenoFluor 232
Table 104: Sysmex Asia Pacific Enters Into Distribution Agreement With DiaSys Diagnostic
Systems 233
Table 105: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 234
Table 106: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test
235
Table 107: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For
AdenoPlus 236
Table 108: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 238
Table 109: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4
POC Test 239
Table 110: One Lambda Enters Into Co-Marketing Agreement With CellTrend 240
Table 111: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics
For ALK Cancer Biomarker 241
Table 112: Insight Genetics Enters Into Licensing Agreement With Kindstar Globalgene
Technology For ALK Screen Biomaker 242
Table 113: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 243
Table 114: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG
Marker 244
Table 115: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor
Cell Technology 245
Table 116: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 246
Table 117: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For
LongRange PCR Kit 247
Table 118: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 248
Table 119: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For
Pressure Cycling Technology 249
Table 120: LipoScience Enters Into Licensing Agreement With Cleveland Clinic 250
Table 121: GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact
Cyclotron And PET Tracer System 251
Table 122: GE Healthcare Enters Into Research Agreement With Clino 252
Table 123: NexDx Enters Into Licensing Agreement With University of California For Epigenetic
Biomarkers 253
Table 124: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 254
Table 125: GeneNews Forms Joint Venture With Shanghai Biochip For Sentinel Centre For
Personalized Medicine 255
Table 126: Life Technologies Enters Into Joint Venture Agreement With DaAn Gene 257

14. 1.2 List of Figures
Figure 1: In Vitro Diagnostics, Market Segmentation 18
Figure 2: In Vitro Diagnostics, China, Overall Revenue ($m), USD Constant, 2004-2018 19
Figure 3: In Vitro Diagnostics Market, China, Revenue Mix ($m), 2011 20
Figure 4: In Vitro Diagnostics Market, China, Category Contribution (%), 2011 21
Figure 5: In Vitro Diagnostics Market, China, Cross-Category Analysis, 2004-2018 22
Figure 6: In Vitro Diagnostics, China, Overall Revenue ($m), USD Constant, Historic, 2004-2011
24
Figure 7: In Vitro Diagnostics, China, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
26
Figure 8: In Vitro Diagnostics, China, Company Share (%), 2011 28
Figure 9: Clinical Chemistry, Market Segmentation 30
Figure 10: Clinical Chemistry Market, China, Revenue Mix ($m), 2011 31
Figure 11: Clinical Chemistry Market, China, Segment Contribution (%), 2011 32
Figure 12: Clinical Chemistry, China, Revenue ($m) USD Constant, by Segment, Historic, 2004-
2011 33
Figure 13: Clinical Chemistry, China, Revenue ($m) USD Constant, by Segment, Forecast, 2011-
2018 35
Figure 14: Clinical Chemisty Analyzers, China, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 37
Figure 15: Clinical Chemisty Analyzers, China, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 39
Figure 16: Urine Analysis, China, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-
2011 41
Figure 17: Urine Analysis, China, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-
2018 43
Figure 18: Clinical Chemistry, China, Company Share (%), 2011 46
Figure 19: Genetic Testing, Market Segmentation 48
Figure 20: Genetic Testing Market, China, Revenue Mix ($m), 2011 49
Figure 21: Genetic Testing Market, China, Segment Contribution (%), 2011 50
Figure 22: Genetic Testing, China, Revenue ($m) USD Constant, by Segment, Historic, 2004-
2011 51
Figure 23: Genetic Testing, China, Revenue ($m) USD Constant, by Segment, Forecast, 2011-
2018 53
Figure 24: Genetic Testing, China, Company Share (%), 2011 56
Figure 25: Haematology Market, Market Segmentation 58
Figure 26: Haematology Market, China, Revenue Mix ($m), 2011 59
Figure 27: Haematology Market, China, Segment Contribution (%), 2011 60
Figure 28: Haematology, China, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
61
Figure 29: Haematology, China, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018

15. 63
Figure 30: Haematology Reagents, China, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 65
Figure 31: Haematology Reagents, China, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 67
Figure 32: Immunohaematology, China, Revenue ($m) USD Constant, by Sub-Segment, Historic,
2004-2011 69
Figure 33: Immunohaematology, China, Revenue ($m) USD Constant, by Sub-Segment, Forecast,
2011-2018 71
Figure 34: Haemostasis, China, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-
2011 73
Figure 35: Haemostasis, China, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-
2018 75
Figure 36: Haematology Rapid Tests, China, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 77
Figure 37: Haematology Rapid Tests, China, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 79
Figure 38: Haematology Cell Counters, China, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 81
Figure 39: Haematology Cell Counters, China, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 83
Figure 40: Haematology, China, Company Share (%), 2011 86
Figure 41: Histology and Cytology Market, Market Segmentation 88
Figure 42: Histology And Cytology Market, China, Revenue Mix ($m), 2011 89
Figure 43: Histology And Cytology Market, China, Segment Contribution (%), 2011 90
Figure 44: Histology And Cytology, China, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 91
Figure 45: Histology And Cytology, China, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 93
Figure 46: Histology And Cytology, China, Company Share (%), 2011 96
Figure 47: Immuno Chemistry Market, China, Revenue Mix ($m), 2011 98
Figure 48: Immuno Chemistry Market, China, Segment Contribution (%), 2011 99
Figure 49: Immuno Chemistry, China, Revenue ($m) USD Constant, by Segment, Historic, 2004-
2011 100
Figure 50: Immuno Chemistry, China, Revenue ($m) USD Constant, by Segment, Forecast, 2011-
2018 102
Figure 51: Disease Specific Immunochemistry, China, Revenue ($m) USD Constant, by Sub-
Segment, Historic, 2004-2011 104
Figure 52: Disease Specific Immunochemistry, China, Revenue ($m) USD Constant, by Sub-
Segment, Forecast, 2011-2018 106
Figure 53: Drugs of Abuse / Toxicology, China, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 108

16. Figure 54: Drugs of Abuse / Toxicology, China, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 110
Figure 55: Endocrinology Tests, China, Revenue ($m) USD Constant, by Sub-Segment, Historic,
2004-2011 112
Figure 56: Endocrinology Tests, China, Revenue ($m) USD Constant, by Sub-Segment, Forecast,
2011-2018 114
Figure 57: Immunochemistry Rapid Tests, China, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 116
Figure 58: Immunochemistry Rapid Tests, China, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2
Contact: sales@reportsandreports.com for more information.